Fully automated dried blood spot sample preparation enables the detection of lower molecular mass peptide and non-peptide doping agents by means of LC-HRMS.
Lange. Tobias T; Thomas. Andreas A; Walpurgis. Katja K; Thevis. Mario M
Key Findings
- Automated dried blood spot (DBS) preparation combined with LC‑HRMS can detect 46 small peptide and non‑peptide drugs, including GHRP‑2 and GHRP‑6.
- Detection limits are very low (0.5‑20 ng/mL), meeting World Anti‑Doping Agency standards.
- A non‑destructive hematocrit measurement using near‑infrared spectroscopy improves quantitative accuracy of DBS testing.
Practical Outcomes
- For biohackers, this study mainly shows that anti‑doping labs can reliably catch GHRP‑2 use from a simple finger‑prick sample, so it isn’t a method to improve dosing or safety. It does not provide new guidance on how to use GHRP‑2 for health or performance, but highlights that detection is feasible at very low concentrations.
Summary
Scientists created a fully automated way to prepare tiny drops of blood on filter paper so they can spot low‑weight peptides like GHRP‑2 using a high‑tech lab test. The method can find these substances at very low levels (0.5‑20 ng/mL) and works even with new blood‑collection devices that use microneedles.
Abstract
The added value of dried blood spot (DBS) samples complementing the information obtained from commonly routine doping control matrices is continuously increasing in sports drug testing. In this project, a robotic-assisted non-destructive hematocrit measurement from dried blood spots by near-infrared spectroscopy followed by a fully automated sample preparation including strong cation exchange solid-phase extraction and evaporation enabled the detection of 46 lower molecular mass (< 2 kDa) peptide and non-peptide drugs and drug candidates by means of LC-HRMS. The target analytes included, amongst others, agonists of the gonadotropin-releasing hormone receptor, the ghrelin receptor, the human growth hormone receptor, and the antidiuretic hormone receptor. Furthermore, several glycine derivatives of growth hormone-releasing peptides (GHRPs), arguably designed to undermine current anti-doping testing approaches, were implemented to the presented detection method. The initial testing assay was validated according to the World Anti-Doping Agency guidelines with estimated LODs between 0.5 and 20 ng/mL. As a proof of concept, authentic post-administration specimens containing GHRP-2 and GHRP-6 were successfully analyzed. Furthermore, DBS obtained from a sampling device operating with microneedles for blood collection from the upper arm were analyzed and the matrix was cross-validated for selected parameters. The introduction of the hematocrit measurement method can be of great value for doping analysis as it allows for quantitative DBS applications by managing the well-recognized "hematocrit effect." Graphical abstract.
Study Information
pubmed
2020
2020-04-16T00:00:00.000Z
10.1007/s00216-020-02634-4
37
43